- A retrospective study suggests that detectable levels of Epstein-Barr virus (EBV) DNA after induction chemotherapy (ICT) are associated with poor survival outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
Why this matters
- Predicting patient prognosis can assist risk stratification and treatment planning.
- Presence of post-ICT EBV DNA was associated with reduced 3-year OS (86.4% vs 93.4%; HR, 2.567; P=.029), distant metastasis-free survival (69.2% vs 93.9%; HR, 5.618; P<.001 and dfs vs hr compared with absence of post-ict ebv dna in multivariate analysis.>
- Post-ICT EBV DNA had areas under the curve of 0.584, 0.717, and 0.659 for predicting 3-year death, metastasis, and disease failure, respectively (P<.001 for all>
- 278 patients with stage III-IV NPC treated with ICT followed by concurrent chemoradiotherapy were analyzed for associations between EBV DNA and survival outcomes.
- Funding: Natural Science Foundation of Guangdong Province; Natural Science Foundation of China; Health & Medical Collaborative Innovation Project of Guangzhou City; Innovation Team Development Plan of the Ministry of Education; Overseas Expertise Introduction Project for Discipline Innovation.
- Retrospective study.